Comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 vs 12q15q21 1 Microdeletion Syndrome C4518344
Clinical comparison between 17 Alpha Hydroxylase 7 20 Lyase Deficiency CN380063 and 12q15q21 1 Microdeletion Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
A rare genetic disorder affecting steroid hormone production. Causes ambiguous genitalia, lack of puberty, and high blood pressure. Requires lifelong hormone replacement therapy.
12q15q21 1 Microdeletion Syndrome C4518344
A rare chromosomal deletion affecting a portion of chromosome 12. Presentation varies and may include developmental concerns and medical issues. Treatment addresses specific symptoms with a multidisciplinary approach.
6 comparison axes
Onset
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
0-18
12q15q21 1 Microdeletion Syndrome C4518344
0-0
Onset patterns differ
Severity
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
severe
12q15q21 1 Microdeletion Syndrome C4518344
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
Chronic
12q15q21 1 Microdeletion Syndrome C4518344
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
No
12q15q21 1 Microdeletion Syndrome C4518344
No
Different transmission
Body System
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
12q15q21 1 Microdeletion Syndrome C4518344
congenital
Same/different system
Category
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
endocrine
12q15q21 1 Microdeletion Syndrome C4518344
genetic
Different category
Bottom line
17-alpha-hydroxylase-7-20-lyase-deficiency-CN380063 and 12q15q21-1-microdeletion-syndrome-C4518344 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 12q15q21 1 Microdeletion Syndrome C4518344 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension is described and may relate to mineralocorticoid excess. | No characteristic blood-pressure finding is established. | Moderate |
| Puberty and genitalia | Ambiguous genitalia and absent or incomplete puberty are described. | Genital or pubertal findings are not established in the source. | High |
| Development | Primarily an endocrine disorder rather than a developmental syndrome. | Variable developmental concerns and other medical issues may occur. | High |
When to favor each condition
Choose 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 when
Hypertension with disordered puberty or ambiguous genitalia
This pattern better matches the described steroid-synthesis disorder.
Moderate
Suspected impaired cortisol and sex-steroid production
The condition specifically affects steroid hormone production.
Moderate
Confirmed diagnosis requiring endocrine replacement planning
Source data state that lifelong hormone replacement is required.
High
Choose 12q15q21 1 Microdeletion Syndrome C4518344 when
Findings present from birth with developmental concerns
The supplied onset is congenital and presentation is variable.
Moderate
Multisystem concerns without a steroid-deficiency pattern
A chromosomal deletion is more consistent than an endocrine enzyme defect.
Moderate
Need for coordinated symptom-specific care
Management is described as multidisciplinary and individualized.
High
How key tests differ
| Test | 17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063 | 12q15q21 1 Microdeletion Syndrome C4518344 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | Disordered adrenal or gonadal steroid production may be found; cutoffs are not supplied. | No characteristic steroid pattern is established. | Abnormal results support evaluation but do not alone confirm either diagnosis. |
| Blood pressure and electrolytes | Hypertension may occur; electrolyte changes need clinical interpretation. | No specific blood-pressure or electrolyte signature is established. | Results are supportive only and must not be treated as a diagnosis. |
| Genetic testing | Targeted testing may confirm the enzyme-deficiency disorder. | Chromosomal microarray or equivalent testing may identify the deletion. | Test choice should follow the suspected mechanism and specialist judgment. |
Prognosis comparison
17 Alpha Hydroxylase 7 20 Lyase Deficiency Cn380063
- Outcome
- Chronic endocrine condition; outcome depends on specialist care, but mortality is not established.
- Factors
- Blood-pressure control, hormone management, and puberty care.
12q15q21 1 Microdeletion Syndrome C4518344
- Outcome
- Chronic congenital condition with a variable course; prognosis is not established.
- Factors
- Developmental needs, associated medical issues, and available support.
Time frame: Lifelong follow-up is expected; exact milestones are not established.
Accurate diagnosis, specialist access, and individualized monitoring.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related effects | Possible if described hypertension is untreated. Not established from the supplied data. Monitoring is clinical; complication rates are not provided. |
| Sex-hormone deficiency | Absent puberty and genital differences are described features. Not established as typical. Distinguish a confirmed endocrine disorder from an isolated abnormal test. |
| Developmental complexity | Not the principal described burden. Variable developmental and medical issues may require coordinated care. The range and severity are not fully established. |
Patient education highlights
- HighConfirm the diagnosis
These are distinct rare conditions. Testing and specialist interpretation are required before assigning either label.
- HighTreatment differs
The enzyme disorder may need lifelong hormone replacement; the deletion is managed by addressing specific symptoms. No doses are stated.
- MediumGenetic counseling
Both may have genetic implications. A genetics professional should explain testing, uncertainty, and family risk.